Type: Highly selective, oral direct acting antiviral (DAA). A purine nucleotide prodrug, AT-527 is designed to inhibit viral RNA dependent RNA polymerase enzyme.
Status: Atea said May 20 that the FDA cleared its IND for AT-527 for the treatment of adults hospitalized with moderate COVID-19 disease, with one or more risk factors for poor outcomes. A Phase II clinical trial (NCT04396106) was recruiting patients as of July 31. The trial is designed to evaluate the safety and efficacy of AT-527 in this patient population.
Atea also said it completed a $215 million Series D financing whose proceeds are intended to support clinical development of the company’s COVID-19 candidate AT-527, in addition to advancing its broader pipeline of treatments for viral diseases. The financing was led by Bain Capital Life Sciences and also included new investors RA Capital Management, Perceptive Advisors, Rock Springs Capital, Adage Capital Management, funds and accounts managed by T. Rowe Price Associates, Redmile Group, and Omega Funds. Existing Atea investors, including Morningside Ventures, Cormorant Asset Management, Ally Bridge Group, and Sectoral Asset Management, as well as other investors also participated in this financing.
According to Atea, AT-527 has shown in vitro and in vivo antiviral activity against several enveloped single-stranded RNA viruses, including human flaviviruses and coronaviruses—while antiviral activity and safety of AT-527 has been shown in Phase II clinical studies of hepatitis C patients.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: